Tannir NM - Search Results

1

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Motzer RJ, et al. Among authors: tannir nm. Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Lancet Oncol. 2019. PMID: 31427204 Free PMC article. Clinical Trial.

2

Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.

Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Tannir N, et al. Cancer. 2006 Aug 1;107(3):497-505. doi: 10.1002/cncr.22038. Cancer. 2006. PMID: 16795067 Free article. Clinical Trial.

3

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.

Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Tannir NM, et al. Cancer. 2006 Nov 1;107(9):2254-61. doi: 10.1002/cncr.22253. Cancer. 2006. PMID: 17029276 Free article. Clinical Trial.

4

Treatment outcomes of small cell carcinoma of the prostate: a single-center study.

Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE, Do KA, Davuluri R, Tannir NM. Spiess PE, et al. Among authors: tannir nm. Cancer. 2007 Oct 15;110(8):1729-37. doi: 10.1002/cncr.22971. Cancer. 2007. PMID: 17786954 Free article. Clinical Trial.

5

A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.

Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. Tannir NM, et al. J Urol. 2008 Sep;180(3):867-72; discussion 872. doi: 10.1016/j.juro.2008.05.017. Epub 2008 Jul 17. J Urol. 2008. PMID: 18635226 Free PMC article. Clinical Trial.

6

Sunitinib-induced acute hemolysis without hypertension: a case report.

Jain R, Mathew P, Wood CG, Tannir NM. Jain R, et al. Among authors: tannir nm. Clin Genitourin Cancer. 2008 Sep;6(2):122-3. doi: 10.3816/CGC.2008.n.019. Clin Genitourin Cancer. 2008. PMID: 18824436

7

Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.

Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. Margulis V, et al. Urology. 2009 Feb;73(2):337-41. doi: 10.1016/j.urology.2008.08.476. Epub 2008 Oct 31. Urology. 2009. PMID: 18950837 Free PMC article. Clinical Trial.

8

Ischemic optic neuropathy associated with low-dose interferon alfa: report of two cases.

Rodney AJ, Gombos DS, Pagliaro LC, Tannir NM. Rodney AJ, et al. Among authors: tannir nm. Am J Clin Oncol. 2009 Feb;32(1):86-7. doi: 10.1097/01.coc.0000227526.96319.50. Am J Clin Oncol. 2009. PMID: 19194130 Free PMC article. No abstract available.

9

Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures.

Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Plimack ER, et al. Cancer. 2009 May 1;115(9):1859-66. doi: 10.1002/cncr.24211. Cancer. 2009. PMID: 19241453 Free PMC article.

10

Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival.

Montero AJ, Diaz-Montero CM, Millikan RE, Liu J, Do KA, Hodges S, Jonasch E, McIntyre BW, Hwu P, Tannir N. Montero AJ, et al. Ann Oncol. 2009 Oct;20(10):1682-7. doi: 10.1093/annonc/mdp054. Epub 2009 Jun 18. Ann Oncol. 2009. PMID: 19541791 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

339 results

Search Page